Le Lézard
Classified in: Health
Subjects: POL, TRD, AVO

3 Reasons Innovation Depends On Strong IP Protections in the TPP



WASHINGTON, June 16, 2015 /PRNewswire-USNewswire/ -- As Congress continues to debate Trade Promotion Authority (TPA), it is important to keep in mind why the Trans-Pacific Partnership (TPP) ? the largest trade deal in history ? can and should help propel the United States (U.S.) into a new era of innovation and productivity in biopharmaceutical manufacturing.

3 Reasons Innovation Depends on Strong IP Protections in the TPP

Our industry's core mission is the discovery of new treatments and cures to help patients live longer, healthier lives. Below are three important facts to keep in mind about why upholding strong intellectual property (IP) protections as part of TPP are vital to the continued discovery and delivery of medicines for the world's patients:

#1. Creating life-saving medicines requires significant investment and resources. 
New medicines are the result of up to 15 years of complex research and development at an average cost of $2.6 billion. The U.S. and other nations must encourage and incentivize the innovation that has the potential to propel today's research into tomorrow's most cutting-edge treatments and cures.

#2. For medical innovation to continue, the TPP must uphold the strong IP protections that currently exist in the U.S. 
The important role of IP ? including a 12-year data protection period for biologics ? is not a new idea. In fact, it was codified in the Affordable Care Act, endorsed by a strong, bipartisan majority in Congress. 

#3. The evidence is overwhelming that the U.S. model works. 
Strong protection of IP is a catalyst for the creation of new medicines for the world's patients. In too many countries, patient access to medicines are stymied not by strong IP protections, but dynamics like poor infrastructure, lack of investment and high tariffs.  The robust IP protections afforded in the United States have helped foster a system whereby the U.S. dominates the pipeline of new drugs in development and, in turn, where generics comprise a healthy 85 percent-plus of the market.

As PhRMA CEO John Castellani notes this week in Morning Consult, we must continue to create an environment ripe for investment today to unlock the promising science of tomorrow. 

This post originally appeared here: http://catalyst.phrma.org/3-reasons-innovation-depends-on-strong-ip-protections-in-the-tpp.

Contact: Tina Stow; 202-835-3460; newsroom@phrma.org

Pharmaceutical Research and Manufacturers of America.

Photo - http://photos.prnewswire.com/prnh/20150616/223597

Logo - http://photos.prnewswire.com/prnh/20091027/PHRMALOGO

 

SOURCE Pharmaceutical Research and Manufacturers of America


These press releases may also interest you

at 12:05
Promius Pharma LLC announces its presentations for the 70th American Academy of Neurology (AAN) Annual Meeting in Los Angeles, CA, April 21-27, 2018. Promius will present 3 platform presentations, with one presentation selected for the "Best of"...

at 11:30
Global pharmaceutical company Mylan N.V. today announced three scientific abstracts from the Glatiramer Acetate development program will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, April 21-27. The...

at 10:00
Laborie Medical Technologies ("Laborie") announced the successful completion of the tender offer by its affiliate Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. ("Parent") to purchase all outstanding shares of...

at 10:00
Injured veterans and their guests enjoyed the last days of winter as they gathered with other warriors to ski cross-country with Wounded Warrior Project® (WWP). "We liked it so much, we're planning on going back on our...

at 09:52
Addressing a standing-room-only audience at Children's National Health System and hundreds more viewing remotely, Sri Sri Ravi Shankar says that people often work to create wealth and, in exchange, lose half their health. Then, they spend half their...

at 09:45
Elekta (EKTA-B.ST) announced today that Proton Partners International Ltd has agreed to procure Elekta MR-linac systems for the network cancer centers across the UK, which they are building to be able to provide cancer patients with the most advanced...




News published on 16 june 2015 at 17:35 and distributed by: